August 30, 2019

August 30, 2019

Can less be more? A heretical approach to chemotherapy is extending cancer patients’ lives

Stat – Aug. 29

But Dr. Robert Gatenby was especially aware of the stakes. An oncologist at Moffitt Cancer Center in Tampa, Fla., he has spent years studying how tumor cells respond to chemotherapy, especially in patients whose cancer has metastasized well beyond the original tumor, as when malignant prostate cells invade bones like gang members expanding their turf.

 

Living with Cancer

North Coast Journal of Politics, People and Art – Aug. 29

“It may be tough to convince patients, even those with an incurable disease, that the best approach is not to kill as many cancer cells as possible but as few as necessary." — James DeGregori and Robert Gatenby, Scientific American, August, 2019

IDSA Honors 105 Distinguished Physicians, Scientists with FIDSA Designation

Infectious Diseases Society of America – Aug. 29

Aliyah Baluch, MD, MSc, Moffitt Cancer Center, Tampa, FL

Bayfront Health medical records now available via Apple's Health app

Citrus County Chronicle – Aug. 27

Other area heath care organizations that also use the app include Advent Health hospitals, Moffitt Cancer Center, University of South Florida Care, Tampa General Hospital, Heart of Florida Regional Medical Center and its physicians groups, Shands satellite facilities and Tenet Health.  

 

Kintai Therapeutics Announces Collaborations with Leading Academic Centers to Identify Novel Targets for Cancer

Globe Newswire – Aug. 27

The company has started to work with Moffitt Cancer Center, Rhode Island Hospital and the University of Cambridge, and is in collaboration discussions with additional cancer centers around the globe. 

 

Largest Study of Prostate Cancer in African American Men Recruiting Participants

OncLive – Aug. 27

Data collection will also take place in these locations: Florida: Moffitt Cancer Center

 

New Drug Combination Shows Promising Activity in Non-Small Cell Lung Cancer Patients

Health News Digest – Aug. 27

In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers describe promising results from an early clinical trial that may offer patients who progress after ICI an additional treatment option. Also posted to Scienmag.com and Medical Xpress.

 

Mesothelioma Study Explores New Treatment When Chemotherapy Fails

Asbestos.com – Aug. 26

The Moffitt Cancer Center is just one of four institutions hosting the trial. The others include Regions Hospital Cancer Center in St. Paul, Minnesota; Karmanos Cancer Center in Detroit; and the University of Maryland Cancer Center in Baltimore.

 

How Common Is Cannabis Use Among Young Adult Cancer Patients?

Liebertpub.com – Aug. 26

Kristine Donovan, PhD, MBA and colleagues from Moffitt Cancer Center, Tampa, FL coauthored the article entitled “Cannabis Use in Young Adult Cancer Patients.” On urine drug testing for a breakdown product of cannabis, they showed that 30% of young adult cancer patients ages 18 to 39 tested positive.

 

Researchers propose genomically-based model for radiotherapy

DotMed – Aug. 26

Researchers at the Moffitt Cancer Center have proposed the development of what they claim would be the first genomically-based model for personalizing radiation oncology treatment for individual patients. 

 

Tampa: Two students win at Florida Invention Convention

The Global Dispatch – Aug. 26

The Florida Invention Convention is sponsored by USF College of Engineering, the National Academy of Inventors (USF Chapter), Moffitt Cancer Center, the Intellectual Property Law Firm of Saliwanchik, and Lloyd and Eisenschenk. 

 

Waiting for the verdict in Noah McAdams’ custody trial, Moffitt experts say timing was key in child’s treatment

WFLA – Aug. 25

Dr. Bijal Shah, an associate at the Moffitt Cancer Center’s and clinical director of the acute lymphoblastic leukemia program, says that there is no scientific research to support the efficacy of treatments with cannabis, which Bland-Ball and McAdams were seeking as an alternative to chemotherapy.

 

Moffitt, Foundation Medicine, Dana-Farber Partner on Genomic Analysis of MCC Patients

Clincalomics – Aug. 23

Researchers at Moffitt Cancer Center have partnered with investigators at the Dana-Farber Cancer Institute and Foundation Medicine to develop what Moffitt said was the largest descriptive genomic analysis to date of patients with Merkel cell carcinoma (MCC).

 

 

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.